Skip to main content

Table 2 Correlation of LINC00961 expression with clinicopathological features in BC patients

From: Evaluation of the potential role of long non-coding RNA LINC00961 in luminal breast cancer: a case–control and systems biology study

Characteristics

No. of cases

LINC00961 expression

p-value

Low (N = 40)

High (N = 39)

Age at diagnose

 ≤ 40

20

11 (28.9%)

9 (24.3%)

0.651

 > 40

55

27 (71.1%)

28 (75.7%)

Tumor size (cm)

 < 2

21

7 (18.9%)

14 (35.9%)

0.248

 2–5

41

22 (59.5%)

19 (48.7%)

 > 5

14

8 (21.6%)

6 (15.4%)

Group

 Luminal A

65

33 (82.5%)

32 (82.1%)

0.958

 Luminal B

14

7 (17.5%)

7 (17.9%)

Grade

 1

10

5 (12.5%)

5 (12.8%)

0.997

 2

55

28 (70.0%)

27 (69.2%)

 3

14

7 (17.5%)

7 (17.9%)

Stage

 I

6

2 (5.3%)

4 (11.4%)

0.466

 II

38

22 (57.9%)

16 (45.7%)

 III

29

14 (36.8%)

15 (42.9%)

Pathology of tumors*

 DCIS

1

1 (4.3%)

0 (0.0%)

0.415

 IDC

38

21 (91.3%)

17 (94.4%)

 ILC

1

0 (0.0%)

1 (5.6%)

 Others

1

1 (4.3%)

0 (0.0%)

Progesterone receptor

 Negative

10

4 (10.0%)

6 (15.4%)

0.472

 Positive

69

36 (90.0%)

33 (84.6%)

Estrogen receptor

 Negative

0

0 (0.0%)

0 (0.0%)

 Positive

79

40 (100.0%)

39 (100.0%)

HER2

 Negative

70

35 (87.5%)

35 (89.7%)

0.754

 Positive

9

5 (12.5%)

4 (10.3%)

Smoking

 No

41

18 (81.8%)

23 (95.8%)

0.012*

 Yes

5

4 (18.2%)

1 (4.2%)

  1. Fisher exact test was used for calculating p-value
  2. *p < 0.05